Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis
In patients with breast cancer bone metastases, denosumab was associated with lower risks of cardiovascular events, fractures, and mortality than those with zoledronic acid.
Authors
- Atsushi Miyawaki (ORCID: https://orcid.org/0000-0001-6126-1464)
- Chikako Iwai (ORCID: https://orcid.org/0000-0001-8260-4200)
- Akira Okada (ORCID: https://orcid.org/0000-0001-5740-4346)
- Toshiaki Isogai (ORCID: https://orcid.org/0000-0002-2172-6447)
- Takaaki Konishi
- Hideo Yasunaga
- Taisuke Jo (ORCID: https://orcid.org/0000-0003-4980-0589)
Institutions
- Department of Health (IE)
- Public Works Research Institute (JP)
- Tokyo Metropolitan Tama Medical Center (JP)
- National Cancer Research Institute (GB)
- The University of Tokyo (JP)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1007/s10549-025-07852-x
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Ministry of Health, Labour and Welfare
- University of Tokyo